RNA interference and retigabine therapy protect against hereditary hearing loss [ 2009 - 2014 ]

Also known as: Genetic and drug therapies for inherited forms of hearing loss

Research Grant

[Cite as]

Researchers: A/Pr Michael Hildebrand (Principal investigator)

Brief description The preservation of hearing function is central to the treatment of individuals who are genetically predisposed to hearing loss. At present only synthetic hearing aids and cochlear implants can provide functional improvement, albeit sub-optimal. The studies described here will seek to prevent hearing loss by reducing the damaging effects of defective genes. Gene therapies that reduce the effect of these defective genes and a drug that enhances the activity of functional genes will be developed.

Funding Amount $AUD 370,522.54

Funding Scheme Early Career Fellowships

Notes CJ Martin Biomedical ECF

Click to explore relationships graph
Viewed: [[ro.stat.viewed]]